Type-specific concordance of detected HPV infection at genital and anal sites, young women and MSM recruited at sexual health clinics in 2009–2019 in the Netherlands
| HPV type | Women (genital/anal) | MSM (genital/anal) | |||||||||
| (+/+) % | (+/−) % | (−/+) % | (−/−) % | Kappa (95% CI) | (+/+) % | (+/−) % | (−/+) % | (−/−) % | Kappa (95% CI) | ||
| High-risk types | |||||||||||
| HPV-16 | 3.1 | 5.1 | 0.7 | 91.1 | 0.49* (0.38 to 0.59) | 1.1 | 2.3 | 7.8 | 88.8 | 0.14 (−0.06 to 0.34) | |
| HPV-18 | 1.4 | 5.1 | 0.8 | 94.7 | 0.40*(0.25 to 0.55) | 1.3 | 2.1 | 6.2 | 90.4 | 0.20 (−0.01 to 0.41) | |
| HPV-31 | 3.0 | 6.3 | 1.2 | 90.2 | 0.41* (0.30 to 0.51) | 0.5 | 1.5 | 5.2 | 92.8 | 0.10 (−0.16 to 0.37) | |
| HPV-33 | 1.5 | 2.6 | 0.8 | 95.2 | 0.45* (0.30 to 0.60) | 0.0 | 1.0 | 3.1 | 96.0 | −0.02 (−0.40 to 0.37) | |
| HPV-35 | 1.3 | 1.3 | 0.8 | 96.6 | 0.53* (0.37 to 0.69) | 0.2 | 0.5 | 2.1 | 97.2 | 0.10 (−0.33 to 0.54) | |
| HPV-39 | 3.1 | 5.6 | 1.2 | 90.2 | 0.44* (0.34 to 0.55) | 0.2 | 1.3 | 2.6 | 95.9 | 0.06 (−0.31 to 0.43) | |
| HPV-45 | 0.9 | 1.7 | 0.5 | 96.9 | 0.43* (0.24 to 0.62) | 0.7 | 0.8 | 2.0 | 96.6 | 0.30 (−0.02 to 0.63) | |
| HPV-51 | 10.7 | 13.1 | 2.6 | 73.6 | 0.49* (0.45 to 0.55) | 1.5 | 3.6 | 7.7 | 87.3 | 0.15 (−0.04 to 0.34) | |
| HPV-52 | 8.8 | 10.5 | 1.9 | 78.8 | 0.52* (0.45 to 0.58) | 1.1 | 1.8 | 5.4 | 91.7 | 0.21 (−0.02 to 0.43) | |
| HPV-56 | 5.2 | 6.6 | 1.7 | 86.5 | 0.51* (0.43 to 0.59) | 0.3 | 1.6 | 3.4 | 94.6 | 0.09 (−0.22 to 0.40) | |
| HPV-58 | 1.6 | 2.6 | 0.4 | 95.4 | 0.50* (0.36 to 0.65) | 0.0 | 0.3 | 1.0 | 98.7 | 0.00 (−0.70 to 0.69) | |
| HPV-59 | 1.3 | 3.4 | 0.9 | 94.3 | 0.36 (0.21 to 0.51) | 0.0 | 0.8 | 2.4 | 98.7 | −0.01 (−0.45 to 0.42) | |
| Low-risk types | |||||||||||
| HPV-6 | 7.2 | 5.1 | 2.8 | 85.0 | 0.60† (0.53 to 0.67) | 2.8 | 4.2 | 10.3 | 82.7 | 0.20 (0.05 to 0.36) | |
| HPV-11 | 0.9 | 1.2 | 0.1 | 97.9 | 0.57* (0.38 to 0.76) | 2.1 | 1.5 | 5.7 | 90.7 | 0.34 (0.15 to 0.53) | |
| HPV-34 | 0.1 | 1.1 | 0.2 | 98.6 | 0.17 (-0.20 to 0.54) | 0.0 | 0.2 | 0.3 | 99.5 | 0.00 (-1.13 to 1.13) | |
| HPV-40 | 0.9 | 1.7 | 0.7 | 96.7 | 0.41* (0.22 to 0.60) | 0.0 | 0.8 | 1.8 | 97.4 | −0.01 (−0.50 to 0.48) | |
| HPV-42 | 0.1 | 1.7 | 0.3 | 97.9 | 0.12 (-0.20 to 0.43) | 0.0 | 0.2 | 0.2 | 99.7 | 0.00 (−1.39 to 1.38) | |
| HPV-43 | 1.6 | 2.4 | 0.9 | 95.0 | 0.47* (0.33 to 0.62) | 0.3 | 2.3 | 1.3 | 96.1 | 0.14 (−0.22 to 0.49) | |
| HPV-44 | 1.6 | 1.7 | 0.5 | 96.2 | 0.58* (0.44 to 0.72) | 0.0 | 1.5 | 1.6 | 96.9 | −0.02 (−0.47 to 0.43) | |
| HPV-53 | 7.7 | 9.7 | 2.7 | 80.0 | 0.49* (0.42 to 0.56) | 0.5 | 1.6 | 4.9 | 93.0 | 0.10 (−0.17 to 0.37) | |
| HPV-54 | 1.9 | 6.2 | 1.5 | 90.4 | 0.30 (0.18 to 0.43) | 0.0 | 2.0 | 1.6 | 96.4 | −0.02 (−0.44 to 0.40) | |
| HPV-66 | 6.6 | 8.3 | 1.9 | 83.2 | 0.51* (0.44 to 0.59) | 1.3 | 2.4 | 4.7 | 91.5 | 0.23 (0.01 to 0.45) | |
| HPV-68 | 1.6 | 3.7 | 0.7 | 94.0 | 0.40* (0.26 to 0.54) | 0.5 | 1.3 | 2.4 | 95.8 | 0.19 (−0.14 to 0.51) | |
| HPV-70 | 0.4 | 1.4 | 0.3 | 97.9 | 0.31 (0.45 to 0.57) | 0.0 | 0.3 | 1.0 | 98.7 | 0.00 (−0.70 to 0.69) | |
| HPV-74 | 1.5 | 2.8 | 0.8 | 94.8 | 0.44* (0.30 to 0.59) | 0.2 | 0.7 | 2.6 | 96.6 | 0.08 (−0.32 to 0.48) | |
The analyses are based on 1492 women and 614 MSM with genital and anal samples collected in 2009, 2011, 2013, 2015, 2017 or 2019. Samples positive for HPV-DNA but with untypable genotypes were excluded from these analyses; +, presence of corresponding HPV genotype; −, absence of corresponding genotype. Total percentages may not add up to 100% due to rounding.
*Moderate concordance.
†High concordance.
HPV, human papillomavirus; MSM, men who have sex with men.